Eos Energy stock falls after Fuzzy Panda issues short report
Phillip Frost, CEO and Chairman of OPKO Health, INC. (NASDAQ:OPK), and Frost Gamma Investments Trust, jointly filed a Form 4, reporting a purchase of 150,000 shares of common stock on October 31, 2025. The shares were bought at a weighted average price of $1.4229, for a total transaction value of $213,435. The prices for the purchases ranged from $1.415 to $1.4299.
Following the transaction, Frost Gamma Investments Trust directly holds 3,568,951 shares of OPKO Health, INC. common stock. Frost Gamma Investments Trust indirectly holds 214,386,448 shares. Frost Nevada Investments Trust indirectly holds 30,127,177 shares.
In other recent news, Opko Health reported its third-quarter 2025 financial results, exceeding earnings expectations. The company achieved a net income of $21.6 million, or $0.03 per share, which was a notable improvement over the anticipated loss of $0.06 per share. However, revenue came in at $151.6 million, slightly below the projected $160.78 million. In addition to these earnings results, Jefferies downgraded Opko Health from Buy to Hold. The downgrade was attributed to concerns about the flat year-over-year guidance for Ngenla, Opko’s growth hormone product developed with Pfizer, projected at $32-35 million for 2026. Jefferies also reduced its price target for the company from $2.00 to $1.60. These developments provide investors with key insights into the company’s current performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.